Concepedia

Janna Minehart

JM

Statistics

Publications

7

Citations

330

H-Index

7

Active since

2015

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Harvard University

New York University

Dana-Farber Cancer Institute

National Institutes of Health

Janna Minehart is an author at Memorial Sloan Kettering Cancer Center specializing in oncology, life sciences, and molecular oncology.

ORCID

Publications per year

2015–2025

7

Publications

7

MLL-AF9– and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C

Nan Zhu, Mo Chen, Rowena Eng et al. · Journal of Clinical Investigation · 2016 · 83 citations · Full text

, , +12

Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL

Matthew C. Stubbs, Won-Il Kim, Megan Bariteau et al. · Clinical Cancer Research · 2015 · 81 citations · Full text

, , +17

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

Julie K. Jadlowsky, Elizabeth O. Hexner, Amy Marshall et al. · Nature Medicine · 2025 · 71 citations

, , +14

Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+).

Claire F. Friedman, Troy Z. Horvat, Janna Minehart et al. · Journal of Clinical Oncology · 2016 · 47 citations

, , +17

Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study

Vivek Murthy, Daniel Katzman, Jun-Chieh J. Tsay et al. · Lung Cancer · 2019 · 19 citations

, , +17

1–5 of 7